Cases – Page 24 – ClaimsFiler

Recent Security Class Actions

Nutanix, Inc. purports to be a cloud computing software company headquartered in San Jose, California known for pioneering its “core” hyper-converged infrastructure (“HCI”) software technology, which combines the components of data center computing (server, storage, and virtualization) into a single scalable machine through software.

Sign up today for FREE to gain access to full case information AND get real time case monitoring for your investment accounts.

Nuance Communications, Inc. is a pioneer and a leading provider of conversational AI and cloud-based ambient clinical intelligence for healthcare providers. Nuance’s products include the Dragon Ambient eXperience, Dragon Medical One and PowerScribe One for radiology reporting, all leading clinical speech recognition SaaS offerings built on Microsoft Azure.

GW Pharmaceuticals, PLC is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from their proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex, which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries. The Company has two primary, more developed products: Epidiolex and Nabiximols (Sativex). GW also has a deep pipeline of additional cannabinoid product candidates and novel compounds, including compounds in Phase 1, Phase 2, and Phase 3 trials.

Sign up today for FREE to gain access to full case information AND get real time case monitoring for your investment accounts.

Washington Prime Group, Inc. is a self-managed and self-administered real estate investment trust (“REIT”) that owns properties and conducts operations through Washington Prime Group, L.P.

Provention Bio, Inc. is a clinical stage biopharmaceutical company that focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. The Company’s product candidates include, among others, PRV-031 teplizumab and mAb, in Phase III clinical trial for the interception of T1D.

Sign up today for FREE to gain access to full case information AND get real time case monitoring for your investment accounts.

Ubiquiti Inc. develops and markets equipment and technology platforms for high capacity Internet access, unified information technology, and consumer electronics.